These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


228 related items for PubMed ID: 25677399

  • 21. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?
    Gilbert RD, Nagra A, Haq MR.
    Med Hypotheses; 2013 Sep; 81(3):400-3. PubMed ID: 23786906
    [Abstract] [Full Text] [Related]

  • 22. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 23. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome.
    Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z.
    Nephrol Dial Transplant; 2013 Sep; 28(9):2237-45. PubMed ID: 23787556
    [Abstract] [Full Text] [Related]

  • 24. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
    Ståhl AL, Sartz L, Karpman D.
    Blood; 2011 May 19; 117(20):5503-13. PubMed ID: 21447825
    [Abstract] [Full Text] [Related]

  • 25. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S.
    Eur J Intern Med; 2013 Sep 19; 24(6):496-502. PubMed ID: 23743117
    [Abstract] [Full Text] [Related]

  • 26. Classical and alternative complement pathway activation in paracoccidioidomycosis.
    de Messias IT, Mohren D.
    J Investig Allergol Clin Immunol; 1994 Sep 19; 4(2):91-5. PubMed ID: 7921333
    [Abstract] [Full Text] [Related]

  • 27. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components.
    Hauser AC, Derfler K, Stockenhuber F, Janata O, Balcke P.
    Clin Sci (Lond); 1990 Nov 19; 79(5):471-6. PubMed ID: 2174314
    [Abstract] [Full Text] [Related]

  • 28. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
    Ferraris JR, Ramirez JA, Ruiz S, Caletti MG, Vallejo G, Piantanida JJ, Araujo JL, Sojo ET.
    Pediatr Nephrol; 2002 Oct 19; 17(10):809-14. PubMed ID: 12376808
    [Abstract] [Full Text] [Related]

  • 29. Complement activation in Puumala hantavirus infection correlates with disease severity.
    Sane J, Laine O, Mäkelä S, Paakkala A, Jarva H, Mustonen J, Vapalahti O, Meri S, Vaheri A.
    Ann Med; 2012 Aug 19; 44(5):468-75. PubMed ID: 21495786
    [Abstract] [Full Text] [Related]

  • 30. [Comparison of complement activation between tuberculous and malignant pleuritis].
    Hidaka K, Abe M, Tanaka T, Mitsuyama T, Hara N, Hara N.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Apr 19; 33(4):379-83. PubMed ID: 7791265
    [Abstract] [Full Text] [Related]

  • 31. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F.
    J Med Genet; 2007 Mar 19; 44(3):193-9. PubMed ID: 17018561
    [Abstract] [Full Text] [Related]

  • 32. Clinical practice. Today's understanding of the haemolytic uraemic syndrome.
    Scheiring J, Rosales A, Zimmerhackl LB.
    Eur J Pediatr; 2010 Jan 19; 169(1):7-13. PubMed ID: 19707787
    [Abstract] [Full Text] [Related]

  • 33. Ex vivo assays to detect complement activation in complementopathies.
    Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA.
    Clin Immunol; 2020 Dec 19; 221():108616. PubMed ID: 33148511
    [Abstract] [Full Text] [Related]

  • 34. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.
    Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H.
    Clin J Am Soc Nephrol; 2009 Dec 19; 4(12):1920-4. PubMed ID: 19820137
    [Abstract] [Full Text] [Related]

  • 35. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.
    Keir LS, Saleem MA.
    Pediatr Nephrol; 2014 Oct 19; 29(10):1895-902. PubMed ID: 23843163
    [Abstract] [Full Text] [Related]

  • 36. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D, Brouwer MC, Daha MR, Hack CE.
    Mol Immunol; 2008 Apr 19; 45(7):1893-9. PubMed ID: 18054386
    [Abstract] [Full Text] [Related]

  • 37. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.
    Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF.
    Transplantation; 2003 Sep 15; 76(5):821-6. PubMed ID: 14501861
    [Abstract] [Full Text] [Related]

  • 38. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
    Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW.
    Blood; 1991 Nov 15; 78(10):2505-13. PubMed ID: 1824247
    [Abstract] [Full Text] [Related]

  • 39. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE, Høgåsen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R.
    Scand J Immunol; 1998 Sep 15; 48(3):312-7. PubMed ID: 9743219
    [Abstract] [Full Text] [Related]

  • 40. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
    Buyon JP, Tamerius J, Belmont HM, Abramson SB.
    Arthritis Rheum; 1992 Sep 15; 35(9):1028-37. PubMed ID: 1418018
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.